title: Clinical effect of gatifloxacin, 200 mg daily, on bacterial community-acquired pneumonia in the elderly.
abstract: The clinical effect of gatifloxacin (GFLX) at 200 mg daily (half of common dosage) on bacterial community-acquired pneumonia in the elderly was examined. Subjects were 30 patients with bacterial community-acquired pneumonia aged 65 years or more (mild, 21 patients; moderate, 9 patients), and GFLX at 100 mg per dose was administered twice daily for 4-14 days. The results included clinical effectiveness in 21 of 21 mildly affected patients (efficacy rate, 100%), in 8 of 9 moderately affected patients (efficacy rate, 88.9%), and 29 of a total of 30 patients (efficacy rate, 96.7%). With regard to bacteriological effect, 28 of 29 strains were eradicated (eradication rate, 96.6%). Abnormal laboratory findings included mild elevations in GPT, GOT, and ALP in only 1 patient. Based on these findings, we concluded that administration of GFLX at 200 mg daily is recommended for bacterial community-acquired pneumonia in the elderly.
authors.affiliation: Center of Respiratory Diseases, Kawasaki Medical School Kawasaki Hospital, 2-1-80 Nakasange, Okayama 700-8505, Japan. info@kawasaki-hp.jp
authors.forename: Niro
authors.initials: N
authors.lastname: Okimoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Kibayashi
authors.forename: Kimihiro
authors.initials: K
authors.lastname: Mimura
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamato
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Kurihara
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Honda
authors.forename: Kohichi
authors.initials: K
authors.lastname: Osaki
authors.forename: Naoko
authors.initials: N
authors.lastname: Asaoka
authors.forename: Hideo
authors.initials: H
authors.lastname: Ohba
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000077734:Gatifloxacin; D006090:Gram-Negative Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000382:microbiology; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D000077734:Gatifloxacin